Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Friday, March 29, 2024 · 699,696,262 Articles · 3+ Million Readers

Genoptix, HistoRx Ink Licensing Deal

February 22, 2010 (FinancialWire) — Genoptix, Inc. (NASDAQ: GXDX), a laboratory service provider, and HistoRx, Inc., a diagnostics firm, said they have inked a multi-year licensing agreement for Aqua technology and several diagnostic assays based on it.

Under the deal, Genoptix has obtained exclusive commercial laboratory rights in the United States to develop and perform three solid tumor assays using HistoRx’s proprietary technology for analysis of fluorescent immunohistochemistry, enabling quantitative assessment of specific biomarkers for patients with certain solid tumors.

Genoptix has also obtained non-exclusive rights to use Aqua technology for the measurement of two additional biomarkers associated with many cancers.

The agreement also enables Genoptix and HistoRx to collaborate on the development of additional assays, which Genoptix would then have the right to commercialize.

Additional details of the deal were not disclosed.

Connecticut-based HistoRx said it has been developing cancer diagnostics based on Aqua technology for five years. The technology quantifies and compartmentalizes tumor markers a component of the assessment of solid tumors for individual cancer patients.

California-based Genoptix is a specialized laboratory service provider focused on delivering diagnostic services to its physician customers, community-based hematologists and oncologists.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release